TNFRSF10B and cancer: TRAILR2 has previously been reported to be present in cancer cell‐derived EVs (Setroikromo et al., 2020) and is known to induce the release of procoagulant microparticles by endothelial cells in response to thrombin (Simoncini et al., 2009).